(2'-methoxybiphenyl-2-yl)methanamine | 292151-99-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2'-methoxybiphenyl-2-yl)methanamine
• 英文别名: 2-(2’-methoxyphenyl)benzylamine；(2'-methoxy-biphenyl-2-yl)-methylamine；(2'-Methoxy[1,1'-biphenyl]-2-yl)methanamine；[2-(2-methoxyphenyl)phenyl]methanamine
• CAS: 292151-99-6
• 化学式: C₁₄H₁₅NO
• 分子量: 213.279
• InChiKey: NWHWUYVVFQTNRX-UHFFFAOYSA-N

物化性质

• 沸点：
  339.5±30.0 °C(Predicted)
• 密度：
  1.073±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  (2'-methoxybiphenyl-2-yl)methanamine 在 叔丁基过氧化氢 作用下， 以 水 、 1,2-二氯乙烷 为溶剂， 反应 18.0h， 以52%的产率得到4-甲氧基-9H-芴-9-酮
  参考文献：
  名称：

  通过无金属 TBHP 促进的 2-（氨基甲基）联苯氧化环化合成高度取代的芴酮。在诺比隆全合成中的应用

  摘要：

  通过不含金属和添加剂的 TBHP 促进的易于获得的N-甲基-2-(氨甲基)联苯和 2-(氨甲基)联苯的交叉脱氢偶联 (CDC)，可以轻松制备高度取代的芴酮，收率基本上相当到良好。该方法与多种官能团（甲氧基、氰基、硝基、氯以及苯酚的 SEM 和 TBS 保护基团）兼容，并进一步用于天然产物诺比隆的首次全合成。

  DOI：

  10.3762/bjoc.17.181
• 作为产物：
  描述：

  2-碘氰基苯 在 aluminum (III) chloride 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 (2'-methoxybiphenyl-2-yl)methanamine
  参考文献：
  名称：

  Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression

  摘要：

  5-HT7 receptor (5-HT7R) is a promising target for the treatment of depression and neuropathic pain. 5-HT7R antagonists exhibited antidepressant effects, while the agonists produced strong anti-hyperalgesic effects. In our efforts to discover selective 5-HT7R antagonists or agonists, N-biphenylylmethyl 2-methoxyphenylpiperazinylalkanamides 1 were designed, synthesized, and biologically evaluated against 5-HT7R. Among the synthesized compounds, N-2'-chlorobiphenylylmethyl 2-methoxyphenylpiperazinylpentanamide 1-8 showed the best binding affinity with a Ki value of 8.69nM and it was verified as a novel antagonist according to functional assays. The compound 1-8 was very selective over 5-HT1DR, 5-HT2AR, 5-HT3R, 5-HT5AR and 5-HT6R and moderately selective over 5-HT1AR, 5-HT1BR and 5-HT2CR. The novel 5-HT7R antagonist 1-8 exhibited an antidepressant effect at a dose of 25mg/kg in the forced swimming test in mice and showed a U-shaped dose-response curve which typically appears in 5-HT7R antagonists such as SB-269970 and lurasidone.

  DOI：

  10.1016/j.bmc.2014.07.026

文献信息

• [EN] PYRIMIDINE AMIDE COMPOUNDS<br/>[FR] COMPOSÉS PYRIMIDINE AMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012123467A1

  公开（公告）日：2012-09-20

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的化合物为式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和紊乱，例如哮喘和慢性阻塞性肺病（COPD）等，具有实用性。
• [EN] ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS<br/>[FR] ACYLGUANIDINES COMME INHIBITEURS DE LA TRYPTOPHAN HYDROXYLASE
  申请人：KAROS PHARMACEUTICALS INC

  公开号：WO2015089137A1

  公开（公告）日：2015-06-18

  The present invention is directed to acylguanidines which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPHl), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及酰基胍，它们是色氨酸羟化酶（TPH）的抑制剂，特别是isoform 1（TPHl），在治疗与外周血清素有关的疾病或紊乱方面具有用处，例如胃肠道、心血管、肺部、炎症、代谢和骨量低等疾病，以及血清素综合征和癌症。
• Biphenyl derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06291465B1

  公开（公告）日：2001-09-18

  The invention relates to compounds of the formula wherein R is hydrogen, lower alkyl, lower alkoxy halogen, amino, —N(R6)2 or trifluoromethyl; R1 is hydrogen lower alkoxy or halogen, R and R1 may be together —CH═CH—CH═CH—; R2 is halogen, lower alkyl or trifluoromethyl; R3 is hydrogen or lower alkyl; R4 is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl; R5 is hydrogen, nitro, amino or —N(R6)2; R6 is hydrogen or lower alkyl, X is —C(O)N(R6)—, —(CH2)nO—, (CH2)nN(R6)—, —N(R6)C(O)— or —N(R6)(CH2)n—; and n is 1 or 2; and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I may be used for the treatment of diseases related to the NK-1 receptor.

  本发明涉及下列化合物的公式：其中，R表示氢、低级烷基、低级烷氧基、卤素、氨基、—N(R6)2或三氟甲基；R1表示氢、低级烷氧基或卤素；R和R1可以是—CH═CH—CH═CH—；R2表示卤素、低级烷基或三氟甲基；R3表示氢或低级烷基；R4表示氢或环状三级胺，可选择性地被低级烷基取代；R5表示氢、硝基、氨基或—N(R6)2；R6表示氢或低级烷基；X表示—C(O)N(R6)—、—(CH2)nO—、(CH2)nN(R6)—、—N(R6)C(O)—或—N(R6)(CH2)n—；n为1或2；以及其药学上可接受的酸加盐。公式I的化合物可用于治疗与NK-1受体相关的疾病。
• PYRIMIDINE AMIDE COMPOUNDS
  申请人：Gillespie Paul

  公开号：US20120270875A1

  公开（公告）日：2012-10-25

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的化合物为公式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和障碍，例如哮喘和COPD等，是有用的。
• DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
  申请人：GENFIT

  公开号：US20150038503A1

  公开（公告）日：2015-02-05

  The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

  本发明提供了新型的6-取代[1,2,4]三唑并[4,3-b]吡啶嗪，这些化合物是Rev-Erb激动剂。这些化合物及其含有的药物组合物是治疗任何需要Rev-Erb激活具有治疗效果的疾病的适当手段，例如炎症和昼夜节律相关疾病或心脏代谢疾病。